Baker McKenzie Advises Bayer on USD 2.45 billion Acquisition of Perfuse Therapeutics

Bayer has received advice from Baker McKenzie about its acquisition of Perfuse Therapeutics, Inc., a US-based biopharmaceutical business that specializes in treating ocular illnesses caused by ischemia. The acquisition aligns with Bayer’s footprint and ophthalmology expertise while also enhancing its pharmaceutical pipeline.